

SEQUENCE LISTING

<110> Allergan Pharmaceuticals International Limited

<120> Treating Ulcerative Colitis with Brazikumab

<130> 32979/53230A PC

<160> 8

<170> PatentIn version 3.5

<210> 1

<211> 124

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Polypeptide

<220>

<221> MISC_FEATURE

<223> Brazikumab heavy chain variable region amino acid sequence

<220>

<221> MISC_FEATURE

<222> (31)..(35)

<223> CDRH1

<220>

<221> MISC_FEATURE

<222> (50)..(67)

<223> CDRH2

<220>

<221> MISC_FEATURE

<222> (99)..(113)

<223> CDRH3

<400> 1

Gln	Val	Gln	Leu	Val	Glu	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly	Arg
1				5				10						15	

Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Ser	Ser	Tyr
			20					25					30		

Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Trp Tyr Asp Gly Ser Asn Glu Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

Ala Arg Asp Arg Gly Tyr Thr Ser Ser Trp Tyr Pro Asp Ala Phe Asp
100 105 110

Ile Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser
115 120

<210> 2
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<220>
<221> MISC_FEATURE
<223> Brazikumab light chain variable region amino acid sequence

<220>
<221> MISC_FEATURE
<222> (23)..(36)
<223> CDRL1

<220>
<221> MISC_FEATURE
<222> (52)..(58)
<223> CDRL2

<220>
<221> MISC_FEATURE
<222> (91)..(101)

<223> CDRL3

<400> 2

Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly Ala Pro Gly Gln
1 5 10 15

Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn Thr Gly Ala Gly
20 25 30

Tyr Asp Val His Trp Tyr Gln Gln Val Pro Gly Thr Ala Pro Lys Leu
35 40 45

Leu Ile Tyr Gly Ser Gly Asn Arg Pro Ser Gly Val Pro Asp Arg Phe
50 55 60

Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala Ile Thr Gly Leu
65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Gln Ser Tyr Asp Ser Ser
85 90 95

Leu Ser Gly Trp Val Phe Gly Gly Gly Thr Arg Leu Thr Val Leu
100 105 110

<210> 3

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Polypeptide

<220>

<221> MISC_FEATURE

<223> Brazikumab CDRH1 amino acid sequence

<400> 3

Ser Tyr Gly Met His
1 5

<210> 4
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<220>
<221> MISC_FEATURE
<223> Brazikumab CDRH2 amino acid sequence

<400> 4

Val Ile Trp Tyr Asp Gly Ser Asn Glu Tyr Tyr Ala Asp Ser Val Lys
1 5 10 15

Gly Arg

<210> 5
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<220>
<221> MISC_FEATURE
<223> Brazikumab CDRH3 amino acid sequence

<400> 5

Asp Arg Gly Tyr Thr Ser Ser Trp Tyr Pro Asp Ala Phe Asp Ile
1 5 10 15

<210> 6
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Polypeptide

<220>

<221> MISC_FEATURE

<223> Brazikumab CDRL1 amino acid sequence

<400> 6

Thr Gly Ser Ser Ser Asn Thr Gly Ala Gly Tyr Asp Val His
1 5 10

<210> 7

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Polypeptide

<220>

<221> MISC_FEATURE

<223> Brazikumab CDRL2 amino acid sequence

<400> 7

Gly Ser Gly Asn Arg Pro Ser
1 5

<210> 8

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic Polypeptide

<220>

<221> MISC_FEATURE

<223> Brazikumab CDRL3 amino acid sequence

<400> 8

Gln Ser Tyr Asp Ser Ser Leu Ser Gly Trp Val
1 5 10